Clinicopathological Significance and Predictive Value of High Intratumoral Tumor Budding in Patients With Breast Carcinoma Treated With Neoadjuvant Chemotherapy

被引:9
作者
Chu, Jinah [1 ]
Kim, Hyun-soo [2 ,4 ]
Do, Sung -Im [1 ,3 ]
机构
[1] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Pathol, Sch Med, Seoul, South Korea
[2] Sungkyunkwan Univ, Samsung Med Ctr, Dept Pathol & Translat Genom, Sch Med, Seoul, South Korea
[3] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Pathol, Sch Med, 29, Saemunan ro, Seoul 03181, South Korea
[4] Sungkyunkwan Univ, Samsung Med Ctr, Dept Pathol & Translat Genom, Sch Med, 81, Irwon ro, Seoul 06351, South Korea
关键词
Breast carcinoma; tumor budding; neoadjuvant; chemotherapy; pathological complete response; EPITHELIAL-MESENCHYMAL TRANSITION; INDEPENDENT PROGNOSTIC-FACTOR; COLORECTAL-CANCER; COMPLETE RESPONSE; SURVIVAL; MICROENVIRONMENT; METAANALYSIS; PROGRESSION; PARAMETER; IMPACT;
D O I
10.21873/anticanres.16397
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: The clinicopathological significance and predictive value of tumor budding (TB) in patients with breast carcinoma (BC) treated with neoadjuvant chemotherapy (NAC) have not been fully elucidated. This study aimed to evaluate the role of TB in predicting the response to NAC in patients with BC. Patients and Methods: We reviewed the pre-NAC biopsy slides obtained from 81 patients with BC and assessed the number of intratumoral TB. The association between TB and response to NAC and clinicopathological characteristics was evaluated. Results: High TB (>= 10 per 20x objective field), which was associated with more frequent lymph node metastasis and lower pathological complete response (pCR) rate, was observed in 57 (70.2%) cases. Multivariate logistic regression analysis revealed that high TB independently predicted non-pCR. Conclusion: High TB is associated with adverse features of BC. High TB on pre-NAC biopsy can be used as a predictive biomarker for non-pCR in NAC-treated patients with BC.
引用
收藏
页码:2323 / 2332
页数:10
相关论文
共 47 条
[1]   Tumor budding in infiltrating breast carcinoma: Correlation with known clinicopathological parameters and hormone receptor status [J].
Agarwal, Radhika ;
Khurana, Nita ;
Singh, Tejinder ;
Agarwal, P. N. .
INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY, 2019, 62 (02) :222-225
[2]   HER2 status in breast cancer: changes in guidelines and complicating factors for interpretation [J].
Ahn, Soomin ;
Woo, Ji Won ;
Lee, Kyoungyul ;
Park, So Yeon .
JOURNAL OF PATHOLOGY AND TRANSLATIONAL MEDICINE, 2020, 54 (01) :34-44
[3]   Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update [J].
Allison, Kimberly H. ;
Hammond, M. Elizabeth H. ;
Dowsett, Mitchell ;
McKernin, Shannon E. ;
Carey, Lisa A. ;
Fitzgibbons, Patrick L. ;
Hayes, Daniel F. ;
Lakhani, Sunil R. ;
Chavez-MacGregor, Mariana ;
Perlmutter, Jane ;
Perou, Charles M. ;
Regan, Meredith M. ;
Rimm, David L. ;
Symmans, W. Fraser ;
Torlakovic, Emina E. ;
Varella, Leticia ;
Viale, Giuseppe ;
Weisberg, Tracey F. ;
McShane, Lisa M. ;
Wolff, Antonio C. .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (12) :1346-+
[4]   The role of epithelial mesenchymal transition and resistance to neoadjuvant therapy in locally advanced rectal cancer [J].
Bhangu, A. ;
Wood, G. ;
Brown, G. ;
Darzi, A. ;
Tekkis, P. ;
Goldin, R. .
COLORECTAL DISEASE, 2014, 16 (04) :O133-O143
[5]   Complete response on MR imaging after neoadjuvant chemotherapy in breast cancer patients: Factors of radiologic-pathologic discordance [J].
Choi, Woo Jung ;
Kim, Hak Hee ;
Cha, Joo Hee ;
Shin, Hee Jung ;
Chae, Eun Young ;
Yoon, Ga Young .
EUROPEAN JOURNAL OF RADIOLOGY, 2019, 118 :114-121
[6]   Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].
Cortazar, Patricia ;
Zhang, Lijun ;
Untch, Michael ;
Mehta, Keyur ;
Costantino, Joseph P. ;
Wolmark, Norman ;
Bonnefoi, Herve ;
Cameron, David ;
Gianni, Luca ;
Valagussa, Pinuccia ;
Swain, Sandra M. ;
Prowell, Tatiana ;
Loibl, Sibylle ;
Wickerham, D. Lawrence ;
Bogaerts, Jan ;
Baselga, Jose ;
Perou, Charles ;
Blumenthal, Gideon ;
Blohmer, Jens ;
Mamounas, Eleftherios P. ;
Bergh, Jonas ;
Semiglazov, Vladimir ;
Justice, Robert ;
Eidtmann, Holger ;
Paik, Soonmyung ;
Piccart, Martine ;
Sridhara, Rajeshwari ;
Fasching, Peter A. ;
Slaets, Leen ;
Tang, Shenghui ;
Gerber, Bernd ;
Geyer, Charles E., Jr. ;
Pazdur, Richard ;
Ditsch, Nina ;
Rastogi, Priya ;
Eiermann, Wolfgang ;
von Minckwitz, Gunter .
LANCET, 2014, 384 (9938) :164-172
[7]   Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching [J].
De Smedt, Linde ;
Palmans, Sofie ;
Andel, Daan ;
Govaere, Olivier ;
Boeckx, Bram ;
Smeets, Dominiek ;
Galle, Eva ;
Wouter, Jasper ;
Barras, David ;
Suffiatti, Madeleine ;
Dekervel, Jeroen ;
Tousseyn, Thomas ;
De Hertogh, Gert ;
Prenen, Hans ;
Tejpar, Sabine ;
Lambrechts, Diether ;
Sagaert, Xavier .
BRITISH JOURNAL OF CANCER, 2017, 116 (01) :58-65
[8]   Tumour budding in colorectal cancer: what do we know and what can we do? [J].
De Smedt, Linde ;
Palmans, Sofie ;
Sagaert, Xavier .
VIRCHOWS ARCHIV, 2016, 468 (04) :397-408
[9]   Immunohistochemical analysis of tumor budding as predictor of lymph node metastasis from superficial esophageal squamous cell carcinoma [J].
Fuchinoue, Kazuhiro ;
Nemoto, Tetsuo ;
Shimada, Hideaki ;
Tochigi, Naobumi ;
Igarashi, Yoshinori ;
Yajima, Satoshi ;
Suzuki, Takashi ;
Oshima, Yoko ;
Shibuya, Kazutoshi .
ESOPHAGUS, 2020, 17 (02) :168-174
[10]   Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR) [J].
Gampenrieder, Simon Peter ;
Peer, Andreas ;
Weismann, Christian ;
Meissnitzer, Matthias ;
Rinnerthaler, Gabriel ;
Webhofer, Johanna ;
Westphal, Theresa ;
Riedmann, Marina ;
Meissnitzer, Thomas ;
Egger, Heike ;
Federspiel, Frederike Klaassen ;
Reitsamer, Roland ;
Hauser-Kronberger, Cornelia ;
Stering, Katharina ;
Hergan, Klaus ;
Mlineritsch, Brigitte ;
Greil, Richard .
BREAST CANCER RESEARCH, 2019, 21 (1)